Xeligekimab in AS: -IL-17A blocker -Phase 3 study on Chinese pts showed sustained efficacy until week 48. -Significant improvement on DAI measures as well. -Fully humanized IgG4 mab may last longer in system and possible less ADAs. Abstract #OP0102 #EULAR2025 @RheumNow https://t.co/vyNHZ9ssFt